Stock Market Reviews

COR (Cencora, Inc.) News

Get the latest news, insights, and market updates on COR (Cencora, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• How Investors May Respond To Cencora (COR) Deepening Its Rare Disease Services Through Curant Collaboration
  On January 22, 2026, Curant Health’s Curant Rare announced a collaboration with Cencora that combines Cencora’s commercialization and logistics capabilities with Curant Rare’s specialty pharmacy and patient-engagement services to support rare disease therapies. This partnership is designed to give rare disease drug developers integrated access to real-world evidence, patient-reported outcomes and market access support, aiming to smooth complex regulatory and access hurdles. With growing...
  Jan 31, 2026 - $COR
• Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum
  Cencora, Inc. (NYSE:COR) is one of the best healthcare stocks to buy for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its price target to $400, citing the company’s strong position in specialty pharmaceuticals and its pending majority acquisition of OneOncology. The firm also highlighted Cencora’s plans […]
  Jan 31, 2026 - $COR
• Exploring Analyst Estimates for Cencora (COR) Q1 Earnings, Beyond Revenue and EPS
  Besides Wall Street's top-and-bottom-line estimates for Cencora (COR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
  Jan 30, 2026 - $COR
• Can Specialty and International Momentum Support Cencora's Q1 Results?
  COR's Q1 outlook is supported by specialty utilization, RCA momentum, and steady international growth, even as GLP-1 tailwinds ease.
  Jan 29, 2026 - $COR
• First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls
  First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls
  Jan 29, 2026 - $COR
• IBD Stock Of The Day: Why Cardinal Health's Momentum Is 'Special' — And Not Over Yet
  Cardinal Health is Monday's IBD Stock Of The Day. Shares are rebounding off their 21-day line, helped by continued biopharma momentum.
  Jan 26, 2026 - $COR
• Here Are the Top Four Blue-Chip Stocks To Buy in 2026, According to WarrenAI
  Investing.com -- Blue chip stocks in the healthcare sector are showing exceptional growth potential according to recent rankings from WarrenAI. The analysis highlights four standout companies that combine strong fundamentals with significant upside potential, making them attractive options in today’s market.
  Jan 25, 2026 - $COR
• Assessing Cencora (COR) Valuation After Strong Returns And Conflicting Fair Value Signals
  What Cencora’s Recent Share Moves Signal for Investors Cencora (COR) has caught investor attention after a steady run, with the stock closing at $353.48 and showing positive total returns over the past year and over the past 3 months. The company reports annual revenue of about $321.3b and net income of $1.6b, alongside annual revenue growth of 6.2% and net income growth of 17.4%. These figures give investors concrete fundamentals to weigh against recent share performance. See our latest...
  Jan 24, 2026 - $COR
• Curant Rare Announces Collaboration with Cencora to Support Commercialization of Rare and Orphan Drug Products
  ATLANTA, January 22, 2026--Curant Rare today announced a strategic collaboration with Cencora, a global pharmaceutical solutions organization, that aims to provide pharmaceutical companies developing rare disease therapies with an integrated solution to support the commercialization of their products.
  Jan 22, 2026 - $COR
• Cencora Elects Ellen Cooper to Its Board of Directors
  CONSHOHOCKEN, Pa., January 22, 2026--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026.
  Jan 22, 2026 - $COR